Literature DB >> 15707730

Application of experimental design methodology in development and optimization of drug release method.

M Kincl1, S Turk, F Vrecer.   

Abstract

The aim of our research was to apply experimental design methodology in the development and optimization of drug release methods. Diclofenac sodium (2-[(2,6-dichlorophenyl)amino]benzeneacetic acid monosodium salt) was selected as a model drug and Naklofen retard prolonged release tablets, containing 100 mg of diclofenac sodium, were chosen as a model prolonged release system. On the basis of previous results, a three-level three-factorial Box-Behnken experimental design was used to characterize and optimize three physicochemical parameters, i.e. rotation speeds of the stirring elements, pH, and ionic strengths of the dissolution medium, affecting the release of diclofenac sodium from the tablets. The chosen dependent variables (responses) were a cumulative percentage of dissolved diclofenac sodium in 2, 6, 12 and 24 h. For estimation of coefficients in the approximating polynomial function, the least square regression method was applied. Afterwards, the information about the model reliability was verified by using the analysis of variance (ANOVA). The estimation of model factors' significance was performed by Student's t-test. For investigation of the shape of the predicted response surfaces and for model optimization, the canonical analysis was applied. Our study proved that experimental design methodology could efficiently be applied for characterization and optimization of analytical parameters affecting drug release and that it is an economical way of obtaining the maximum amount of information in a short period of time and with the fewest number of experiments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15707730     DOI: 10.1016/j.ijpharm.2004.07.041

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Development of microsponges for topical delivery of mupirocin.

Authors:  Netal Amrutiya; Amrita Bajaj; Madhu Madan
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

2.  In situ forming formulation: development, evaluation, and optimization using 3(3) factorial design.

Authors:  Ramesh C Nagarwal; A Srinatha; Jayanta K Pandit
Journal:  AAPS PharmSciTech       Date:  2009-07-28       Impact factor: 3.246

Review 3.  Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation.

Authors:  Felipe M González-Fernández; Annalisa Bianchera; Paolo Gasco; Sara Nicoli; Silvia Pescina
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

4.  Optimizing PET Glycolysis with an Oyster Shell-Derived Catalyst Using Response Surface Methodology.

Authors:  Yonghwan Kim; Minjun Kim; Jeongwook Hwang; Eunmi Im; Geon Dae Moon
Journal:  Polymers (Basel)       Date:  2022-02-09       Impact factor: 4.329

5.  Application of Response Surface Methodology for Modeling of Postweld Heat Treatment Process in a Pressure Vessel Steel ASTM A516 Grade 70.

Authors:  Prachya Peasura
Journal:  ScientificWorldJournal       Date:  2015-10-15

6.  A designed experiments approach to optimization of automated data acquisition during characterization of bacteria with MALDI-TOF mass spectrometry.

Authors:  Lin Zhang; Connie M Borror; Todd R Sandrin
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

7.  Formulation optimization of arecoline patches.

Authors:  Pao-Chu Wu; Pi-Ju Tsai; Shin-Chen Lin; Yaw-Bin Huang
Journal:  ScientificWorldJournal       Date:  2014-02-23

8.  Development and optimization of enteric coated mucoadhesive microspheres of duloxetine hydrochloride using 3(2) full factorial design.

Authors:  Anupama Setia; Sahil Kansal; Naveen Goyal
Journal:  Int J Pharm Investig       Date:  2013-07

9.  Formulation and optimisation of lamivudine-loaded Eudragit® S 100 polymer-coated pectin microspheres for colon-specific delivery.

Authors:  Satheesh Vilas; Sivasudha Thilagar
Journal:  IET Nanobiotechnol       Date:  2021-02-02       Impact factor: 2.050

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.